Less than 10% of individuals that would benefit from obesity jabs like Wegovy can access them, warns the global health agency as it publishes its inaugural recommendations on the medications.
Considering in excess of 1,000,000,000 individuals worldwide now living with obesity, it is advocating for increased and just access to these injectable treatments.
Per forecasts, over two billion could be obese by 2030 unless action is taken.
"The new guidelines acknowledges that excess weight is a chronic disease that can be treated with thorough and lifelong care," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and supply-chain constraints are key barriers to universal availability to the jabs that can aid individuals in losing substantial weight, says the organization.
Skinny Jab Scarcity
Even in the present best projected case, the supply of such drugs could only cover approximately 100 million people – under 10% of the global need, as stated by the WHO.
The guideline urges countries and companies to increase access, by approaches like patent sharing.
Exclusive production rights on a key compound – the primary ingredient of the drug Wegovy – is scheduled to end in multiple nations in 2026.
How Weight-Loss Injections Operate
GLP-1 drugs mimick a biological compound to reduce digestion speed, suppress the appetite and enhance feelings of fullness so users consume fewer calories.
People usually start to lose weight within a few weeks of starting on the weekly injections.
Evidence points to patients may put most of the weight back on within a year of stopping the treatment, as their usual hunger return.
To be carrying excess weight raises your likelihood for experiencing diseases, such as type 2 diabetes, heart disease, brain attack, and certain cancers.
Obesity concerns individuals in countries worldwide and was responsible for 3.7 million deaths worldwide in 2024, per the health agency.
